Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial - Concepedia

Concepedia

Publication | Closed Access

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

362

Citations

27

References

2019

Year

Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, B. Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt

Systemic TreatmentGuselkumab Versus SecukinumabClinical DermatologyPharmacotherapyDermatologyExperimental DermatologyMedicineModerate-to-severe PsoriasisPhase 3

References

	Year	Citations

Page 1

Page 1